Leveraging Adeno-Associated Viruses (AAVs) in therapeutic approaches for monogenic neurological diseases
Supplied by PerkinElmer on Wednesday, 07 September, 2022
Within the field of neurological diseases, there is great interest in looking at rare diseases of monogenic origin with the hope of developing disease-modifying gene therapies, as opposed to treatments for symptom management. Therefore, using relatively tunable systems like recombinant AAVs, scientists are also exploring in vivo gene delivery in parallel to ex vivo.
Learn about key strategies and innovations in this space that are enabling advanced gene therapy.
Monitoring secrets from North America’s largest healthcare services company
Learn about the cutting edge solutions McKesson implemented to optimise processes and deliver...
The solution for a seamless quantitative bioanalysis
High selectivity is a critical element of successful quantitative bioanalysis. Recent...
Advantages of Wavelength Scanning in Fluorescence and Absorbance Assays
EnVision® Multilabel Plate Reader, widely used in biological assay studies across the field...
